Fidelis Capital Partners LLC Grows Position in Johnson & Johnson (NYSE:JNJ)

Fidelis Capital Partners LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 26,605 shares of the company’s stock after purchasing an additional 2,460 shares during the period. Fidelis Capital Partners LLC’s holdings in Johnson & Johnson were worth $4,228,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of JNJ. Epoch Investment Partners Inc. raised its position in shares of Johnson & Johnson by 2.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 575,286 shares of the company’s stock worth $84,084,000 after acquiring an additional 11,630 shares in the last quarter. Mount Yale Investment Advisors LLC raised its holdings in Johnson & Johnson by 0.4% in the second quarter. Mount Yale Investment Advisors LLC now owns 22,147 shares of the company’s stock worth $3,237,000 after purchasing an additional 96 shares in the last quarter. Frank Rimerman Advisors LLC lifted its position in shares of Johnson & Johnson by 1,811.6% during the second quarter. Frank Rimerman Advisors LLC now owns 31,541 shares of the company’s stock valued at $4,610,000 after buying an additional 29,891 shares during the last quarter. Prospector Partners LLC boosted its holdings in shares of Johnson & Johnson by 1.0% in the 2nd quarter. Prospector Partners LLC now owns 66,134 shares of the company’s stock valued at $9,666,000 after buying an additional 660 shares in the last quarter. Finally, ProShare Advisors LLC grew its position in shares of Johnson & Johnson by 9.8% in the 2nd quarter. ProShare Advisors LLC now owns 1,651,733 shares of the company’s stock worth $241,417,000 after buying an additional 147,609 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $164.16 on Friday. The firm’s fifty day moving average is $161.30 and its two-hundred day moving average is $154.16. The firm has a market cap of $395.08 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.80 earnings per share. Research analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Friday. Morgan Stanley upped their target price on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.